Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial.

Intravenous VCN-01 combined with gemcitabine and nab-paclitaxel improves overall survival in metastatic pancreatic ductal adenocarcinoma, with median OS reaching 10.8 months in the FAS population.

• Why it matters: Pancreatic ductal adenocarcinoma has limited treatment options and poor prognosis, highlighting the need for more effective first-line therapies. Understanding whether VCN-01 enhances survival when added to standard chemotherapy could inform future treatment strategies.
• What they did: A randomized phase 2b trial compared two doses of intravenous VCN-01 plus GnP versus GnP alone in 101 patients, assessing overall survival, progression-free survival, and safety, with primary endpoints in the intent-to-treat and full analysis sets.
• The result: The primary efficacy endpoint was met in the FAS population, with median OS of 10.8 months versus 8.6 months (HR=0.57, P=0.055), and progression-free survival of 7.0 versus 4.6 months (HR=0.55, P=0.011), supporting further evaluation of VCN-01 plus GnP as a first-line treatment.